Board of Directors

  • Hannah Bell, RN, BSN

    Currently: Women's Health nurse in a labor, delivery, recovery, and postpartum unit

    Registered Nurse since 2021

    B.S. Psychology, BYU
    B.S. Nursing, Northeastern University 

    Previously: Birth Assistant at a freestanding birth center

    Off-Hours: Gardening; writing; two young children

  • Ess Page, MS

    Currently: Entrepreneur, investor, majority owner of hospitality and recreational properties

    B.S. Biology, BYU
    M.S. Environmental Education, University of Arizona

    Off-hours: Gardening; Board Member for The Cooper Center, an outdoor education non-profit in Tucson

  • Glenn Cornett, MD, PhD

    Currently: Serial entrepreneur (CNS, cardiovascular); successful exit from earlier company in 3.5 years via asset sale to Gilead

    Structuring and valuation on deals driving  >$1 billion in value: Milnacipran (fibromyalgia drug), iloprost (pulmonary hypertension)

    M.D. w/ Distinction in Research, University of Michigan

    PhD. Neuroscience, UCLA

    Previously: McKinsey; Eli Lilly; Razorfish; Los Alamos

    Off-hours: Running, music; Founder/Ex. Dir., SpectrumNYC.org; >2,400 concerts since 2012

Operations Team

  • Jeff Yablon: Operations, Clinical

    > 500 clinical trials

    35 years of industry experience – general management, clinical trials

    Women’s health: Luprolide; HPV test

    Recently General Manager of two Malaysia-based CROs (now in US)

    Previously: VP Global Bus. Dev., Parexel; COO/labs, ICON; Marketing Director, Abbott; Captain, US Army

  • Justus Bingham: Drug Development

    > 100 clinical trials

    > 15 years of experience – project mgmt, PK / PD, study design, clinical pharmacology, modeling/ simulation, regulatory, & statistics to accelerate drug development.

    Previously: Genentech, Gilead, Lilly, Pfizer, Certara, U Illinois Supercomputing Center, et al.

  • Alpheus Bingham, PhD: CMC/innovation

    25 years at Eli Lilly, including:

    (1) VP over External Innovation (deals, alliances), R&D strategy, portfolio analysis, Japan R&D; (2) Co-founder, e.Lilly Incubator and Investment Fund – originated 9 companies

    Open innovation thought leader; co-author, “The Open Innovation Marketplace” and “One Smart Crowd;” Founder, CEO, Innocentive

    PhD. Organic Chemistry, Stanford

  • G. Thomas Stromberg: Strategy, Legal

    Recently retired as transactional partner at 
    AmLaw 50 law firm

    Over 41 years of corporate transactional experience handling structuring, financings, transformational transactions and general corporate matters

    AV peer rated and named by LA Business Journal as one of LA’s 500 most influential people

  • Brian Meshkin: Corporate Development

    Award-winning MedTech CEO and Entrepreneur (OCTANe, OCBJ, SmartCEO, EY)

    Managing Partner, Profound Ventures

    Previously: Eli Lilly, Johnson & Johnson, Prometheus Laboratories, Proove Biosciences

    >20 publications; inventor of record for 12 existing/pending patents in precision medicine

  • Kevin Palisi: Organization

    20+ years of talent acquisition & HR experience in life science and healthcare w/ Korn Ferry, Ancora Search, Magellan Health

    Advisor to and co-founder of early-stage life science companies including Intronx, RIGImmune, Travin Bio

    MBA. Marketing, University of New Haven

Advisors

  • Frances Quirk, PhD

    Academic, researcher, executive leader

    Professor at University of St Andrews, UK and University of New England, Aus.

    Previously: Pfizer R&D Outcomes Research and Clinical Development; international clinical trials including Viagra/women’s health

    Women’s Health, quality of life, psychometric

    BSc. Psychology, University of London

    PhD. Non-clinical Medicine, University of London

  • Mark J. Alvino

    Life sciences investment and advisory: Hudson Square Capital (President; current), Griffin Securities (Managing Director), SCO Capital (Managing Director)

    Women’s health experience includes: Cardiovascular risk awareness/prevention; interstitial cystitis treatment;  cervical cancer test; sexual health; fertility

  • Jay Kranzler, MD, PhD

    Chair & CEO, Urica Therapeutics

    CEO, Cypress Bioscience; developed and launched 2nd fibromyalgia drug

    25 years as CEO of public companies

    Founder, McKinsey healthcare practice

    Pfizer VP External Innovation

    Thought leader on CNS treatments

    M.D. Yale

    PhD. Neuroscience, Yale